Precipio (PRPO)

• Market cap: $16.4M
• 1 day: -3.64%
• 5 days: -3.21%
• 1 month: 55.00%
• 3 months: 56.34%
• 6 months: 86.43%
• Year to date: 102.43%
• 1 year: 87.39%
• 5 years: -51.99%
• 10 years: -99.60%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Employees: 60

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more capital invested

Capital invested by funds: $402K [Q4 2024] → $644K (+$242K) [Q1 2025]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

20% more funds holding

Funds holding: 10 [Q4 2024] → 12 (+2) [Q1 2025]

2.56% more ownership

Funds ownership: 4.94% [Q4 2024] → 7.49% (+2.56%) [Q1 2025]